Bristol-Myers Squibb Co (NYSE:BMY) a large American
pharmaceutical giant. Its prescription drug portfolio includes treatments for a
wide variety of ailments, including HIV, cancer, diabetes, cardiovascular
disease, and psychiatric disorders.
It grew through a series of acquisitions over the years to
be a prominent drug company, even before the pandemic.
You may buy its drugs, but is Bristol-Myers Squibb stock a
Buy?
Although it has an impressive portfolio, the government’s
Operation Warp Speed coronavirus vaccine program overlooked BMY.
Its CEO attached the company to OWS through auxiliary
programs, but it didn’t receive the billion-dollar research grants its
contemporaries did.
Still, it took it on the chin and continued pushing to
involve itself in the accompanying research and development.
Bristol-Myers Squibb Is A Top 100 Company
Bristol-Myers Squibb was founded in 1887 and is a component
of both the S&P 100 and S&P 500 indices. It was one of the first
companies to focus on high-quality drugs with a high level of purity and pushed
for many of the regulations we have today.
Over the years, it grew through a series of mergers and
acquisitions of smaller companies involved in therapeutics, biosciences, and
other related markets.
Today, it’s one of the 100 largest corporations in the
United States, with over 30,000 employees. The company has a broad pipeline of
pharmaceuticals and biologic products.
Comments
Post a Comment